Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biosearch Technologies Launches New, ISO Certified GMP Production Facility

Published: Thursday, April 18, 2013
Last Updated: Thursday, April 18, 2013
Bookmark and Share
Biosearch Technologies, Inc. (Biosearch) announced the relocation of its GMP manufacturing process into a new, state-of-the-art GMP production facility in Novato, California.

The 30,000 square foot facility was developed to further expand processes and controls relevant to medical device and molecular diagnostic customers.

“The GMP production facility is designed to incorporate the environmental and access controls, linear production flow and clean room processes critical for the controlled manufacture of highly-qualified diagnostic components, reagents and kits,” said Ron Cook, President and CEO of Biosearch Technologies.  “Our new facility allows us to continue to support our diagnostic customers in a manner fully compliant with customer and regulatory requirements.  This advanced facility also introduces pharmaceutical scale lyophilization capabilities allowing for state-of-the-art processing of molecular diagnostic assays in large scale single batches and all format types.”

In addition to the relocation to the new GMP production facility, Biosearch has successfully completed certification to ISO 13485:2003.  This certification confirms that Biosearch has developed, implemented and maintains a Quality Management System able to meet the stringent requirements of medical device and molecular diagnostic manufacturing.

“Certification to ISO 13485 is a significant milestone for Biosearch and its GMP and Commercial Services production group,” said Jason Erickson, Director of Quality at Biosearch Technologies.  “We have taken great strides to ensure a robust Quality Management System and successful certification to this standard demonstrates our commitment to quality at all levels within our organization.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!